Using molecular dynamics simulation to explore the binding of the three potent anticancer drugs sorafenib, streptozotocin, and sunitinib to functionalized carbon nanotubes.


Journal

Journal of molecular modeling
ISSN: 0948-5023
Titre abrégé: J Mol Model
Pays: Germany
ID NLM: 9806569

Informations de publication

Date de publication:
14 May 2019
Historique:
received: 13 01 2018
accepted: 02 04 2019
entrez: 16 5 2019
pubmed: 16 5 2019
medline: 21 11 2019
Statut: epublish

Résumé

The adsorption of the anticancer drugs sorafenib (SF), streptozotocin (STZ), and sunitinib (STB) on pristine and functionalized carbon nanotubes (FCNTs, functionalized with valine or phenylalanine moieties) was investigated using molecular dynamics simulation. Descriptors such as the van der Waals (vdW) energy, the number of hydrogen bonds, and the radial distribution function were considered. It was found that the type of functional group on the nanotube is a key influence on the vdW interaction energy between a drug molecule and a nanotube. In addition, the positions of the functional groups on a nanotube are a key influence on the adsorption of drug molecules on its surface. Our study indicated that the adsorption of STZ on CNT/FCNTs involves a partial π-π interaction and hydrogen bonding, whereas SF and STB are adsorbed on CNT/FCNTs through π-π stacking and hydrogen bonding. Our results suggest that altering the functionalization of the nanotube surface can affect the drug-nanotube interaction. The results reported here should aid attempts to optimize the design of novel CNT-based drug carriers.

Identifiants

pubmed: 31089817
doi: 10.1007/s00894-019-4024-5
pii: 10.1007/s00894-019-4024-5
doi:

Substances chimiques

Antineoplastic Agents 0
Nanotubes, Carbon 0
Water 059QF0KO0R
Streptozocin 5W494URQ81
Sorafenib 9ZOQ3TZI87
Sunitinib V99T50803M

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

159

Références

J Med Chem. 2003 Mar 27;46(7):1116-9
pubmed: 12646019
Nat Biotechnol. 2003 Oct;21(10):1166-70
pubmed: 14520401
Curr Opin Chem Biol. 2005 Dec;9(6):674-9
pubmed: 16233988
Chemistry. 2006 May 3;12(14):3869-75
pubmed: 16502454
Nat Rev Drug Discov. 2006 Oct;5(10):835-44
pubmed: 17016424
J Nucl Med. 2007 Jul;48(7):1180-9
pubmed: 17607040
Eur J Med Chem. 2008 Sep;43(9):1837-46
pubmed: 18201805
Nat Nanotechnol. 2008 Jul;3(7):423-8
pubmed: 18654567
Cancer Res. 2008 Aug 15;68(16):6652-60
pubmed: 18701489
Oncogene. 2009 Jan 8;28(1):85-94
pubmed: 18794803
Chem Rev. 2009 Jul;109(7):3012-43
pubmed: 19422222
J Chromatogr A. 2009 Jul 24;1216(30):5709-14
pubmed: 19540504
J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Nov 15;877(30):3926-9
pubmed: 19836316
Nano Res. 2009 Feb 1;2(2):85-120
pubmed: 20174481
J Phys Chem B. 2010 Aug 5;114(30):9882-93
pubmed: 20614923
Nanomedicine (Lond). 2010 Oct;5(8):1277-301
pubmed: 21039202
N Engl J Med. 2011 Feb 10;364(6):501-13
pubmed: 21306237
Biosens Bioelectron. 2011 Apr 15;26(8):3438-43
pubmed: 21324667
J Comput Chem. 2011 Aug;32(11):2359-68
pubmed: 21541964
Int J Pharm. 2011 Oct 31;419(1-2):339-46
pubmed: 21843612
Nanomedicine (Lond). 2012 Feb;7(2):231-43
pubmed: 22106855
J Comput Chem. 2012 Feb 15;33(5):580-92
pubmed: 22162017
Chem Commun (Camb). 2013 Jan 25;49(7):734-6
pubmed: 23232330
J Dent Res. 2013 Jul;92(7):575-83
pubmed: 23677650
ACS Nano. 2013 Aug 27;7(8):6735-46
pubmed: 23829596
Adv Drug Deliv Rev. 2013 Dec;65(15):2045-60
pubmed: 23933617
Adv Drug Deliv Rev. 2013 Dec;65(15):1964-2015
pubmed: 23954402
Acta Biomater. 2013 Dec;9(12):9243-57
pubmed: 23958782
Lancet Oncol. 2014 Sep;15(10):e420
pubmed: 25328943
ACS Nano. 2014 Nov 25;8(11):11290-304
pubmed: 25343751
J Chem Theory Comput. 2008 Mar;4(3):435-47
pubmed: 26620784
J Mol Model. 2016 Mar;22(3):62
pubmed: 26898713
J Mol Model. 2017 Feb;23(2):36
pubmed: 28120117
Biochim Biophys Acta Gen Subj. 2017 Jun;1861(6):1617-1641
pubmed: 28238734
Phys Chem Chem Phys. 2017 Mar 29;19(13):9300-9312
pubmed: 28323298
J Mol Model. 2017 Aug;23(8):222
pubmed: 28702805
Drug Discov Today. 2018 Feb;23(2):235-250
pubmed: 29031623
Anal Biochem. 2018 Feb 1;542:76-83
pubmed: 29191385
J Biomol Struct Dyn. 2019 Jul;37(10):2487-2497
pubmed: 30052134
Ann Intern Med. 1973 Jul;79(1):108-18
pubmed: 4352784
Br J Cancer. 1995 Feb;71(2):363-5
pubmed: 7530987
Ann Intern Med. 1994 Feb 15;120(4):302-9
pubmed: 8291824
J Mol Graph. 1996 Feb;14(1):33-8, 27-8
pubmed: 8744570

Auteurs

Narjes Dehneshin (N)

Chemistry Department, University of Birjand, Birjand, Iran. NarjesDehneshin66@gmail.com.

Heidar Raissi (H)

Chemistry Department, University of Birjand, Birjand, Iran.

Zohre Hasanzade (Z)

Chemistry Department, University of Birjand, Birjand, Iran.

Farzaneh Farzad (F)

Chemistry Department, University of Birjand, Birjand, Iran.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs
Photosynthesis Ribulose-Bisphosphate Carboxylase Carbon Dioxide Molecular Dynamics Simulation Cyanobacteria
Humans Male Female Health Knowledge, Attitudes, Practice Middle Aged
Animals Dietary Fiber Dextran Sulfate Mice Disease Models, Animal

Classifications MeSH